Timothy J. Scannell Sells 4,666 Shares of Stryker Co. (SYK) Stock

Share on StockTwits

Stryker Co. (NYSE:SYK) insider Timothy J. Scannell sold 4,666 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $186.71, for a total transaction of $871,188.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Timothy J. Scannell also recently made the following trade(s):

  • On Tuesday, April 16th, Timothy J. Scannell sold 4,666 shares of Stryker stock. The shares were sold at an average price of $192.40, for a total transaction of $897,738.40.
  • On Monday, March 18th, Timothy J. Scannell sold 4,666 shares of Stryker stock. The shares were sold at an average price of $193.28, for a total transaction of $901,844.48.
  • On Tuesday, February 19th, Timothy J. Scannell sold 4,666 shares of Stryker stock. The shares were sold at an average price of $186.25, for a total transaction of $869,042.50.

Shares of SYK stock traded down $0.67 during trading hours on Friday, hitting $184.96. 487,563 shares of the company’s stock were exchanged, compared to its average volume of 1,302,334. The company has a market capitalization of $69.27 billion, a PE ratio of 25.30, a price-to-earnings-growth ratio of 2.26 and a beta of 0.84. Stryker Co. has a 12-month low of $144.75 and a 12-month high of $199.85. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.30 and a current ratio of 2.12.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 EPS for the quarter, topping the consensus estimate of $1.84 by $0.04. The firm had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.51 billion. Stryker had a net margin of 25.38% and a return on equity of 26.72%. The business’s revenue was up 8.5% compared to the same quarter last year. During the same period last year, the firm posted $1.68 earnings per share. On average, research analysts predict that Stryker Co. will post 8.15 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 1.12%. The ex-dividend date of this dividend is Thursday, June 27th. Stryker’s dividend payout ratio (DPR) is presently 28.45%.

Hedge funds have recently bought and sold shares of the business. Farmers National Bank purchased a new position in shares of Stryker during the first quarter worth approximately $25,000. Cable Hill Partners LLC purchased a new position in shares of Stryker during the first quarter worth approximately $30,000. RPG Investment Advisory LLC increased its stake in shares of Stryker by 160.0% in the first quarter. RPG Investment Advisory LLC now owns 156 shares of the medical technology company’s stock worth $31,000 after buying an additional 96 shares during the period. ERTS Wealth Advisors LLC purchased a new position in shares of Stryker in the fourth quarter worth $25,000. Finally, Northwest Wealth Management LLC increased its stake in shares of Stryker by 103.6% in the fourth quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock worth $26,000 after buying an additional 86 shares during the period. 74.71% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Tuesday. Canaccord Genuity raised their target price on shares of Stryker from $190.00 to $195.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Deutsche Bank raised their target price on shares of Stryker from $181.00 to $208.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Oppenheimer raised their target price on shares of Stryker from $183.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Stryker in a research note on Friday, January 18th. Six equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $196.85.

WARNING: This story was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://weekherald.com/2019/05/17/timothy-j-scannell-sells-4666-shares-of-stryker-co-syk-stock.html.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: How to Profit and Limit Losses With Stop Orders

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.